Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|unspecified PD-1 antibody||Experimental PD-1 antibody||Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 93|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CTNNB1 act mut||hepatocellular carcinoma||decreased response||unspecified PD-1 antibody||Clinical Study - Cohort||Actionable||In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).||30373752|
|FBXW7 R505C||melanoma||predicted - resistant||unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, a melanoma cell line expressing FBXW7 R505C in a mouse model conferred resistance to treatment with an unspecified PD-1 antibody, demonstrating increased tumor volume and decreased survival compared to models with wild-type FBXW7 (PMID: 32371478).||32371478|
|BRAF mutant||lung non-small cell carcinoma||predicted - sensitive||unspecified PD-1 antibody||Clinical Study - Cohort||Actionable||In a clinical study, mutant BRAF correlated with prolonged duration on immune checkpoint inhibitor therapy compared to wild-type BRAF in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).||detail...|
|FBXW7 loss||colon cancer||predicted - resistant||unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, an FBXW7-deficient colon cancer cell line in a mouse model was resistant to treatment with an unspecified PD-1 antibody, demonstrating poor survival and decreased inhibition of tumor growth compared to models with wild-type FBXW7 (PMID: 32371478).||32371478|
|FBXW7 loss||melanoma||predicted - resistant||unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, an FBXW7-deficient melanoma cell line in a mouse model was resistant to treatment with an unspecified PD-1 antibody, demonstrating increased tumor volume and poor survival compared to models with wild-type FBXW7 (PMID: 32371478).||32371478|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02843165||Phase II||unspecified PD-L1 antibody unspecified CTLA4 antibody unspecified PD-1 antibody||Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease||Active, not recruiting||USA||0|
|NCT04001101||Phase II||unspecified PD-1 antibody||Anti-PD-1 +/- RT for MSI-H Solid Tumors||Withdrawn||USA||0|
|NCT04116320||Phase I||unspecified PD-1 antibody Imiquimod Imiquimod + unspecified PD-1 antibody||Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003)||Recruiting||USA||0|
|NCT04093323||Phase II||alphaDC1 + Celecoxib + Interferon alpha-2b + Rintatolimod Ipilimumab unspecified PD-L1 antibody unspecified PD-1 antibody||Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma||Recruiting||USA||0|